文献速递脊柱关节炎

轴性脊柱关节炎患者接受肿瘤坏死因子抑制剂治疗期间ASDAS-CRP非活动性疾病的预测因素:来自EuroSpA协作网的数据

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
PubMed 文献 · Semin Arthritis Rheum · 2022-08-10

研究纳入15个欧洲注册中心中首次启用肿瘤坏死因子抑制剂的轴性脊柱关节炎患者,在汇总数据(n=21,196)中分析6个月ASDAS非活动性疾病和临床重要改善以及12个月药物留存率的基线预测因素。汇总数据中6个月ASDAS非活动性疾病率为26%、ASDAS临床重要改善率为51%,12个月药物留存率为65%,并识别出九个共同基线预测因素。

要点

  • 汇总数据中6个月ASDAS非活动性疾病率为26%、ASDAS临床重要改善率为51%,12个月药物留存率为65%。
  • ASDAS非活动性疾病的预测因素包括年龄、性别、吸烟状态、HLA-B27、TNF开始年份、CRP、HAQ、BASDAI疲劳和脊柱疼痛。
  • 九个共同基线预测因素在15个欧洲注册中心数据中可被识别,提示可能在不同轴性脊柱关节炎人群中具有普遍性。

核心结论

  • 在15个欧洲注册中心的数据中可识别肿瘤坏死因子抑制剂治疗反应和依从性的共同基线预测因素,提示这些因素可能在不同轴性脊柱关节炎人群中具有普遍性。

研究设计与样本

  • 研究纳入15个欧洲注册中心中首次启用肿瘤坏死因子抑制剂的轴性脊柱关节炎患者,收集基线人口学和临床特征,按注册中心分别及在汇总数据中采用多重插补数据的逻辑回归分析结局。

主要发现

  • 汇总数据集(n=21,196)中,有可用数据的患者6个月ASDAS非活动性疾病率为26%(n=9,845)、ASDAS临床重要改善率为51%(n=6,948)、12个月药物留存率为65%(n=21,196)。
  • ASDAS非活动性疾病的比值比(95%置信区间)为:年龄每增加1岁0.97(0.97-0.98),男性对比女性1.88(1.60-2.22),当前吸烟对比非吸烟0.76(0.63-0.91),HLA-B27阳性对比阴性1.51(1.20-1.91),TNF开始年份2015-2018对比2009-2014为1.24(1.06-1.45),CRP>10对比≤10 mg/l为1.49(1.25-1.77),健康评估问卷(HAQ)每增加1个单位0.77(0.58-1.03),Bath强直性脊柱炎疾病活动指数(BASDAI)疲劳每增加1毫米0.99(0.99-1.00),BASDAI脊柱疼痛每增加1毫米0.99(0.99-1.99)。
  • 九个共同基线预测因素可预测ASDAS非活动性疾病、ASDAS临床重要改善和12个月药物留存率。

关键数值与推荐

  • ASDAS非活动性疾病定义为ASDAS-CRP非活动性疾病。
  • 临床重要改善定义为ASDAS临床重要改善(CII)。
  • 药物留存率定义为12个月药物留存率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. METHODS: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. RESULTS: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97-0.98), men vs. women: 1.88 (1.60-2.22), current vs. non-smoking: 0.76 (0.63-0.91), HLA-B27 positive vs. negative: 1.51 (1.20-1.91), TNF start year 2015-2018 vs. 2009-2014: 1.24 (1.06-1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58-1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99), respectively CONCLUSION: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ørnbjerg LM, Linde L, Georgiadis S, et al. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Semin Arthritis Rheum. 2022. PMID: 35985172. doi:10.1016/j.semarthrit.2022.152081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。